$Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose$

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose

<b>Background and Aim:</b> Controlling the hepatic inflammation of metabolic dysfunction-associated steatotic liver disease (MASLD) is important to prevent serious condition. Pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has demonstrated effectiveness a...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Satoshi Shinozaki, Kouichi Miura, Toshiyuki Tahara, Hironori Yamamoto
التنسيق:	مقال
اللغة:	English
منشور في:	MDPI AG 2025-02-01
سلاسل:	Metabolites
الموضوعات:	non-alcoholic fatty liver disease non-alcoholic steatohepatitis pemafibrate dyslipidemia metabolic dysfunction-associated steatotic liver disease
الوصول للمادة أونلاين:	https://www.mdpi.com/2218-1989/15/2/100

مواد مشابهة

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
حسب: Satoshi Shinozaki, وآخرون
منشور في: (2023-06-01)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
حسب: Suguru Ikeda, وآخرون
منشور في: (2021-12-01)

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
حسب: Hiroki Ono, وآخرون
منشور في: (2024-04-01)

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
حسب: Takanobu Iwadare, وآخرون
منشور في: (2022-11-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
حسب: Masahiro Kikuchi, وآخرون
منشور في: (2024-09-01)

Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect
حسب: Azuma Watanabe, وآخرون
منشور في: (2023-10-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
حسب: K. L. Raikhelson, وآخرون
منشور في: (2024-05-01)

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
حسب: Chavdar S. Pavlov, وآخرون
منشور في: (2024-05-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
حسب: Katharina Staufer, وآخرون
منشور في: (2023-07-01)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
حسب: Ryosuke Sugimoto, وآخرون
منشور في: (2023-02-01)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
حسب: Hidekatsu Yanai, وآخرون
منشور في: (2022-02-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
حسب: Yvonne Burmeister, وآخرون
منشور في: (2023-12-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
حسب: Ana Sandoval-Rodriguez, وآخرون
منشور في: (2024-02-01)

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
حسب: Renuka Suvarna, وآخرون
منشور في: (2024-08-01)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
حسب: Natasa Paklar, وآخرون
منشور في: (2023-11-01)

Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
حسب: Takao Miwa, وآخرون
منشور في: (2024-06-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
حسب: Takeshi Hatanaka, وآخرون
منشور في: (2021-10-01)

Prevalence of metabolically associated steatotic liver disease in the elderly: analysis and perspectives
حسب: O. O. Karshina
منشور في: (2025-01-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
حسب: Valeria Michelle Fernández-Garibay, وآخرون
منشور في: (2025-01-01)

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients
حسب: Singh Deepak, وآخرون
منشور في: (2010-07-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
حسب: Gi-Ae Kim, وآخرون
منشور في: (2023-10-01)

Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake
حسب: Emil Deleuran Hansen, وآخرون
منشور في: (2025-01-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
حسب: Shyam Patel, وآخرون
منشور في: (2025-01-01)

Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD
حسب: Takanobu Iwadare, وآخرون
منشور في: (2024-05-01)

A new name for an old problem. Metabolic dysfunction-associated steatotic liver disease - review of literature
حسب: Adrian Kruszewski, وآخرون
منشور في: (2024-07-01)

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
حسب: Jeffrey V. Lazarus, وآخرون
منشور في: (2025-01-01)

Glycyrrhizinic Acid and Phosphatidylcholine Combination as a Preventive Therapy for Experimental Murine Non-Alcoholic Steatohepatitis
حسب: Veronika A. Prikhodko, وآخرون
منشور في: (2024-01-01)

Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
حسب: Maryam Mahjoubin-Tehran, وآخرون
منشور في: (2021-08-01)

Case series showing the safety and changes in lipid profiles of hemodialysis patients with hypertriglyceridemia after pemafibrate administration
حسب: Rino Okada, وآخرون
منشور في: (2024-12-01)

Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
حسب: Mira Thing, وآخرون
منشور في: (2024-01-01)

Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation
حسب: Kristoffer Kjærgaard, وآخرون
منشور في: (2024-03-01)

Liver Injury and Cell Survival in Non-Alcoholic Steatohepatitis Regulated by Sex-Based Difference through B Cell Lymphoma 6
حسب: Akihide Kamiya, وآخرون
منشور في: (2022-11-01)

Revolutionizing cardiometabolic health: the dual power of GLP-1 receptor agonists and SGLT2 inhibitors: a review article
حسب: G. Tomova-Lyutakova, وآخرون
منشور في: (2024-12-01)

Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report
حسب: Nahum Méndez-Sánchez, MD, PhD, وآخرون
منشور في: (2003-10-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
حسب: Yu-Ming Cheng, وآخرون
منشور في: (2024-12-01)

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
حسب: Ju Hyun Shim
منشور في: (2020-04-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
حسب: O. M. Drapkina, وآخرون
منشور في: (2014-10-01)

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
حسب: Reddemma Sandireddy, وآخرون
منشور في: (2024-07-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
حسب: Gong Feng, وآخرون
منشور في: (2025-03-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
حسب: Jessica M. Rubino, وآخرون
منشور في: (2025-01-01)